Treatment with SR18662 significantly lessens development and proliferation of CRC cells. SR18662 exhibits enhanced efficacy in minimizing viability of numerous CRC mobile strains. Movement cytometry Assessment adhering to SR18662 treatment method shows an increase in cells captured in both S or G2/M phases on the cell cycle and a major increase in